Anne Floquet

Anne Floquet

UNVERIFIED PROFILE

Are you Anne Floquet?   Register this Author

Register author
Anne Floquet

Anne Floquet

Publications by authors named "Anne Floquet"

Are you Anne Floquet?   Register this Author

47Publications

1661Reads

12Profile Views

Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.

Int J Cancer 2019 04 13;144(8):1962-1974. Epub 2018 Nov 13.

Inserm, Paris, France.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.31921
Publisher Site
http://dx.doi.org/10.1002/ijc.31921DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587727PMC
April 2019

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

N Engl J Med 2018 12 21;379(26):2495-2505. Epub 2018 Oct 21.

From the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.); University of Milan-Bicocca, European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico, Milan (N.C.), and Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica, Rome (G.S.) - both in Italy; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (B.-G.K.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (A. Oaknin), and M.D. Anderson Cancer Centre Madrid, Madrid (A.G.-M.) - both in Spain; University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, Australia (M.F.); St. Petersburg City Oncology Dispensary, St. Petersburg, Russia (A. Lisyanskaya); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris (A.F., A. Leary), Institut Bergonié, Comprehensive Cancer Center, Bordeaux (A.F.), and Gustave-Roussy Cancer Campus, Villejuif (A. Leary) - all in France; the Netherlands Cancer Institute, Amsterdam (G.S.S.); Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (C.G.), the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London (S.B.), and AstraZeneca, Cambridge (R.B.) - all in the United Kingdom; Princess Margaret Cancer Centre, Toronto (A. Oza); Memorial Sloan Kettering Cancer Center, New York (C.A.); Froedtert and the Medical College of Wisconsin, Milwaukee (W.B.); Women and Infants Hospital, Providence, RI (C.M., P.D.); Dana-Farber Cancer Institute, Boston (J.L.); and AstraZeneca, Gaithersburg, MD (E.S.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1810858
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1810858DOI Listing
December 2018

[Thyroid carcinoma on struma ovarii: Diagnosis and treatment].

Bull Cancer 2018 Mar 17;105(3):281-289. Epub 2018 Feb 17.

Institut Bergonié, département de médecine nucléaire et de cancérologie thyroidienne, 229, cours de l'Argonne, 33076 Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2017.11.014DOI Listing
March 2018

Traitement des rechutes tardives du cancer de l’ovaire.

Bull Cancer 2017 May;104 Suppl 1:S24-S31

Institut de cancérologie des hospices civils de Lyon (IC-HCL) ; CITOHL ; centre hospitalier Lyon-Sud ; université de Lyon ; université Claude-Bernard Lyon 1 ; faculté de médecine Lyon-Sud ; EMR UCBL/HCL 3738 Lyon, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551173015
Publisher Site
http://dx.doi.org/10.1016/S0007-4551(17)30159-5DOI Listing
May 2017

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).

J Clin Oncol 2016 07 6;34(21):2516-25. Epub 2016 Jun 6.

Christian Kurzeder and Andreas du Bois, Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Kliniken Essen Mitte, Essen; Frederik Marmé, AGO and University Hospital Heidelberg, Heidelberg; Joern Rau and Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg; Sven Mahner, AGO and University Medical Center Hamburg-Eppendorf, Hamburg; Sandra Polleis, AGO Study Group, Wiesbaden, Germany; Isabel Bover, Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Hospital Son Llàtzer, Palma de Mallorca; Pilar Barretina-Ginesta, GEICO and Catalan Institute of Oncology, Girona; Josep M. del Campo, GEICO and Vall d'Hebron University Hospital, Barcelona; Antonio Gonzalez-Martin, GEICO and MD Anderson Cancer Center Spain, Madrid, Spain; Patricia Pautier, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Institut Gustave Roussy, Villejuif; Anne Floquet, GINECO and Institut Bergonié, Bordeaux, France; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan Bicocca-European Institute of Oncology; Domenica Lorusso, Multicenter Italian Trials in Ovarian Cancer and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, National Cancer Institute, Milan, Italy; Petronella Ottevanger, Dutch Gynecological Oncology Group and Radboud University Medical Center, Nijmegen, the Netherlands; Maria Bjurberg, Nordic Society of Gynecological Oncology and Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden; Christian Marth, AGO-Austria and Innsbruck Medical University, Innsbruck, Austria; Ignace Vergote, AGO and University Hospital Leuven, Leuven, Belgium; and Lydie Bastière-Truchot, Nicolas Martin, Mikkel Z. Oestergaard, and Astrid Kiermaier, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.0787DOI Listing
July 2016

Dry Matter Production, Nutrient Cycled and Removed, and Soil Fertility Changes in Yam-Based Cropping Systems with Herbaceous Legumes in the Guinea-Sudan Zone of Benin.

Scientifica (Cairo) 2016 30;2016:5212563. Epub 2016 Jun 30.

Centre de Coopération Internationale en Recherche Agronomique pour le Développement (CIRAD), 34398 Montpellier Cedex 5, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/5212563DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944082PMC
July 2016

GENESIS: a French national resource to study the missing heritability of breast cancer.

BMC Cancer 2016 Jan 12;16:13. Epub 2016 Jan 12.

Inserm, U900, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-2028-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711059PMC
January 2016

SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.

Am J Surg Pathol 2015 Sep;39(9):1197-205

*Department of BioPathology §Medical Oncology **Surgery, Institut Bergonié †INSERM U916 ‡Université de Bordeaux, Bordeaux ∥Department of Pathology, Centre JF Leclerc, Comprehensive Cancer Centre, Dijon ¶Department of Pathology, University Hospital of Caen, Caen #Department of Pathology, University Hospital of Strasbourg, Strasbourg, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000475DOI Listing
September 2015

Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.

Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S67-72

*EORTC, Department of Oncology, KU Leuven and Department of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium; †GINECO, Department of Medical Oncology, Institut Bergonié, Bordeaux, France; ‡ANZGOG, Department of Clinical Oncology, Prince of Wales Hospital, Randwick, Australia; §NSGO, Department for Gynecologic Oncology and Institute for Medical Informatics, Oslo University Hospital, Oslo, Norway; ∥AGO, Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ¶KGOG, Women's Cancer Clinic, Division of Gynecologic Oncology, Institute of Women's Life Medical Science, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, South Korea; #GOG, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, United States of America, **GINECO, Centre Léon Bérard, Lyon, France; ††SGCTG, Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, United Kingdom; ‡‡ANZGOG, Department of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand; §§DGOG, Department of Medical Oncology, Academic Medical Center, Amsterdam, the Netherlands; and ∥∥MRCP, FRCR, Department of Oncology, University College Hospital London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000205DOI Listing
November 2014

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

J Clin Oncol 2014 Oct 15;32(30):3374-82. Epub 2014 Sep 15.

Andreas du Bois, Rainer Kimmig, Klaus H. Baumann, Christian Kurzeder, Ulrich Canzler, Philipp Harter, AGO Ovarian Cancer Study Group (AGO); Andreas du Bois, Christian Kurzeder, Philipp Harter, Kliniken Essen Mitte; Rainer Kimmig, West German Tumor Center, University of Duisburg-Essen, Essen; Joern Rau, Carmen Schade-Brittinger, Coordinating Center for Clinical Trials, Philipps-University of Marburg; Klaus H. Baumann, University of Marburg, Marburg; Ulrich Canzler, University Hospitals Carl Gustav Carus, Dresden, Germany; Anne Floquet, Isabelle Ray-Coquard, Marie-Ange Mouret-Reynier, Anne Lesoin, Eric Pujade-Lauraine, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens; Anne Floquet, Institut Bergonié, Bordeaux; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Marie-Ange Mouret-Reynier, Centre Jean Perrin, Clermont-Ferrand; Anne Lesoin, Centre Oscar Lambret, Lille; Eric Pujade-Lauraine, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Jae-Weon Kim, Jae-Hoon Kim, Korean Gynecologic Oncology Group; Jae-Weon Kim, Seoul National University; Jae-Hoon Kim, Yonsei University; Byoung-Gie Kim, Samsung Medical Center, Seoul, Republic of Korea; Josep M. del Campo, Ivan Diaz-Padilla, Spanish Ovarian Cancer Research Group; Josep M. del Campo, Vall d'Hebron University Hospital, Barcelona; Ivan Diaz-Padilla, Centro Integral Oncologico Clara Campal, HM Hospitales, Madrid, Spain; Michael Friedlander, Paul Vasey, Australian and New Zealand Gynecological Oncology Group; Michael Friedlander, The Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales; Paul Vasey, Wesley Medical Centre, Auchenflower, Queensland, Australia; Sandro Pignata, Giovanni Scambia, Multicenter Italian Trials in Ovarian Cancer; Sandro Pignata, Istituto Nazionale Tumori Fondazione G. Pascale, Naples; Nicoletta Colombo, Mario Negri Gynecologic Oncology Group and University of Milan-Bicocca and European Institute of Oncology, Milan

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.7348DOI Listing
October 2014

Pulsed-dose-rate brachytherapy for uterine cervix carcinoma: 10 years of experience with 226 patients at a single institution.

Brachytherapy 2013 Nov-Dec;12(6):542-9. Epub 2013 Jul 20.

Department of Radiation Oncology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2013.05.003DOI Listing
May 2014

Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.

Ann Surg Oncol 2014 Feb 20;21(2):629-36. Epub 2013 Sep 20.

Department of Surgery, Institut Bergonié, Regional Cancer Centre, 229 Cours de l'Argonne, 33076, Bordeaux, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-013-3278-xDOI Listing
February 2014

[Hereditary ovarian carcinomas: clinico-biological features and treatment].

Bull Cancer 2014 Feb;101(2):167-74

Institut Bergonié, département de chirurgie, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2014.1888DOI Listing
February 2014

Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study.

Cancer Chemother Pharmacol 2014 Jan 20;73(1):61-8. Epub 2013 Oct 20.

Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33076, Bordeaux, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2317-4DOI Listing
January 2014

Functional decline in older patients with cancer receiving first-line chemotherapy.

J Clin Oncol 2013 Nov 23;31(31):3877-82. Epub 2013 Sep 23.

Stéphanie Hoppe, Marianne Fonck, Laurent Hoppenreys, Cécile Mertens, Nadine Houédé, Carine A. Bellera, Anne Floquet, Marie-Noëlle Fabry, Camille Chakiba, Simone Mathoulin-Pélissier, and Pierre Soubeyran, Institut Bergonié; Muriel Rainfray, Jean-Frédéric Blanc, Cécile Mertens, and Alain Ravaud, Centre Hospitalier Universitaire; Muriel Rainfray, Christèle Blanc-Bisson, Alain Ravaud, Simone Mathoulin-Pélissier, and Pierre Soubeyran, University of Bordeaux, Bordeaux; Joël Ceccaldi, Centre Hospitalier, Libourne; Yves Imbert and Luc Vogt, Centre Hospitalier, Agen; Laurent Cany, Clinique Francheville, Périgueux; and Jérôme Dauba, Centre Hospitalier, Mont de Marsan, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.7430DOI Listing
November 2013

[Advanced endometrial carcinoma: primary debulking surgery or neoadjuvant chemotherapy?].

Bull Cancer 2012 Jan;99(1):43-9

Institut Bergonié, CLCC Aquitaine, département d'oncogynécologie, Bordeaux Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2011.1515DOI Listing
January 2012

Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined?

Eur J Obstet Gynecol Reprod Biol 2011 Dec 10;159(2):407-12. Epub 2011 Aug 10.

Department of Surgery, Institut Bergonié, Regional Cancer Centre, 229, cours de l'Argonne, 33076 Bordeaux Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2011.07.014DOI Listing
December 2011

First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?

Oncology 2009 23;77(5):318-27. Epub 2009 Nov 23.

Department of Medical Oncology, Institut Bergonié, South-West Comprehensive Cancer Center, Bordeaux, France. debled @ bergonie.org

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000260904DOI Listing
January 2010